[ad_1]
Moscow:
Russia’s sovereign wealth fund and Indian pharmaceutical firm Hetero have agreed to provide over 100 million doses per yr in India of the Sputnik V vaccine in opposition to COVID-19, in keeping with an announcement on the Sputnik V Twitter account on Friday.
Hetero and the Russian Direct Investment Fund (RDIF), which has been backing the vaccine and advertising it globally, plan to start out manufacturing of Sputnik V in India firstly of 2021, the assertion mentioned.
Phase II-III trials are ongoing in India, the assertion mentioned. Drugmaker Dr Reddy’s Laboratories Ltd has mentioned it expects late-stage trials to be accomplished by as early as March 2021.
(Except for the headline, this story has not been edited by NDTV employees and is revealed from a syndicated feed.)
[ad_2]
Source hyperlink